Short QT Syndrome (SQTS)
Details
Short QT syndrome is a rare autosomal dominant channelopathy characterised by accelerated cardiac repolarization producing a QTc ≤360 ms (or ≤320 ms as a standalone diagnostic criterion). Eight genetic subtypes are defined, predominantly caused by gain-of-function mutations in potassium channel genes (KCNH2, KCNQ1, KCNJ2) or loss-of-function mutations in calcium channel subunits (CACNA1C, CACNB2, CACNA2D1). The syndrome predisposes to atrial fibrillation, ventricular fibrillation, and sudden cardiac death — approximately 30% of patients present with SCA/SCD as the first clinical manifestation. Variant detection rates are low (~20–25%), and a broad list of acquired phenocopies must be excluded before a hereditary diagnosis is made.
Key Facts
Epidemiology and Genetics
- Prevalence: 0.02–0.1% of adults; male predominance; low penetrance. (sources/channelopathies-jaha-2025, rating: high)
- 8 subtypes: SQT1–3 caused by gain-of-function mutations in K⁺ channel genes (KCNH2, KCNQ1, KCNJ2); SQT4–6 by loss-of-function in Ca²⁺ channel subunits (CACNA1C, CACNB2, CACNA2D1); SQT7 by SCN5A R689H loss-of-function; SQT8 by SLC4A3 loss-of-function affecting Cl⁻/HCO₃⁻ exchange. (sources/channelopathies-jaha-2025)
- ClinGen-curated core genes (4 genes): KCNH2 (definitive), KCNQ1 (moderate), KCNJ2 (moderate), SLC4A3 (moderate). SLC4A3 encodes the cardiac chloride-bicarbonate exchanger AE3; loss-of-function causes reduced sarcolemmal localisation → intracellular alkalinisation → shortened AP duration. Two families identified with the identical SLC4A3 variant to date. (sources/arrhythmia-genetics-mgenetik-2025, rating: high)
- Variant detection rate: ~20–25% in index patients. A confirmed pathogenic variant (ACMG class 4/5) scores 2 points in the Gollob diagnostic score. (sources/arrhythmia-genetics-mgenetik-2025)
- Clinical outcomes: ~30% of SQTS patients have SCA/SCD as the first clinical manifestation. Life-threatening arrhythmias occur equally across genotypes. Syncope is more frequent in males; atrial arrhythmias (AF, flutter, palpitations) are distributed equally by sex. (sources/arrhythmia-genetics-mgenetik-2025)
- SQTS belongs to the spectrum of early repolarization syndrome. (sources/channelopathies-jaha-2025)
Pathophysiology — Subtypes and Mechanisms
- Core gain-of-function mechanism (SQT1–3): Increased outward K⁺ currents — IKr (KCNH2/SQT1), IKs (KCNQ1/SQT2), IK1 (KCNJ2/SQT3) — accelerate the action potential plateau and shorten the absolute refractory period, reducing repolarization reserve and creating a re-entrant arrhythmia substrate. (sources/channelopathies-jaha-2025, rating: high)
- Loss-of-function calcium channel subtypes (SQT4–6): Reduced inward ICa,L via CACNA1C, CACNB2, or CACNA2D1 loss-of-function also abbreviates the AP plateau. These subtypes show phenotypic overlap with Brugada syndrome — particularly CACNA1C and CACNB2 variants, which may present with combined SQTS/BrS overlap features. (sources/channelopathies-jaha-2025)
- SLC4A3/SQT8: Loss-of-function reduces sarcolemmal AE3 exchanger → impaired Cl⁻/HCO₃⁻ exchange → intracellular alkalinisation → net AP shortening. Mechanistically distinct from all ion channel subtypes. (sources/arrhythmia-genetics-mgenetik-2025)
ECG Features
- Characteristic morphology: Short or absent ST segments; asymmetrical T-waves with high amplitude and prolonged Tpeak-to-T-end (TpTe) interval. The tall, narrow T-wave and abbreviated ST segment are visually distinctive. (sources/repolarisation-jaccep-2023, rating: high)
- Risk markers within SQTS: Symptomatic patients (SCA survivors) show shorter J-point-to-T-peak intervals and a higher TpTe/QTc ratio than asymptomatic patients. Elevated TpTe/QTc reflects increased transmural dispersion of repolarization — the functional arrhythmogenic substrate. (sources/repolarisation-jaccep-2023)
- QTc severity does not predict arrhythmic risk in SQTS — unlike LQTS, the magnitude of QTc shortening does not stratify cardiac event probability. Risk stratification must rely on clinical history, family history, and structural assessment rather than QTc alone. (sources/repolarisation-jaccep-2023)
Diagnosis
- ESC 2022 Class I criteria:
- QTc ≤360 ms plus ≥1 of: (a) pathogenic mutation, (b) family history of SQTS, (c) VT/VF survival without structural heart disease
- ESC 2022 Class IIa criteria:
- QTc ≤320 ms alone: consider SQTS
- QTc 320–360 ms + arrhythmic syncope: consider SQTS
- (sources/VA-SCD-ESC-2022, rating: very high)
- Gollob diagnostic score — key domains: QTc ≤370 ms (1 pt), ≤350 ms (2 pts), ≤330 ms (3 pts); J-point-to-T-peak interval <120 ms (1 pt); clinical history (VF/pVT 2 pts, unexplained syncope 1 pt, AF 1 pt); family history of SQTS or sudden death <40 years (1 pt); pathogenic mutation (2 pts). (sources/arrhythmia-genetics-mgenetik-2025)
- Genetic testing: Class I (ESC 2022). (sources/VA-SCD-ESC-2022)
- ILR in young SQTS patients: Class IIa (ESC 2022). (sources/VA-SCD-ESC-2022)
- PES for SCD risk stratification: NOT recommended (Class III) — programmed electrical stimulation has not been validated for arrhythmic risk stratification in SQTS (unlike its Class IIb role in Brugada syndrome). (sources/VA-SCD-ESC-2022)
- Acquired phenocopies and exogenous causes to exclude before hereditary diagnosis:
- Electrolyte/metabolic: hyperkalemia, hypercalcemia, acidosis, primary hyperparathyroidism, congenital adrenal hyperplasia, hyperthyroidism, milk-alkali syndrome, vitamin A intoxication
- Systemic/genetic: congenital lactase deficiency, primary carnitine deficiency (SLC22A5), Klinefelter syndrome (47,XXY)
- Iatrogenic/toxic: digitalis intoxication, hyperthermia, ATP K⁺ channel openers (pinacidil, levcromakalim), rufinamide (anti-convulsant)
- (sources/arrhythmia-genetics-mgenetik-2025)
Management
- ICD: Primary therapy for symptomatic patients with life expectancy >30 years. Class I after SCA or documented sustained VT/VF (ESC 2022). (sources/channelopathies-jaha-2025, sources/VA-SCD-ESC-2022)
- Quinidine: First-line pharmacotherapy; prolongs QTc via IKr blockade. Hydroquinidine shares this mechanism. Effective in SQTS1. ESC 2022 Class IIb — when ICD is contraindicated/refused, or in asymptomatic patients with a family history of SCD. (sources/channelopathies-jaha-2025, sources/VA-SCD-ESC-2022)
- Amiodarone and sotalol: ineffective in SQTS1 despite being IKr blockers — gain-of-function KCNH2 mutation alters drug-channel binding kinetics, preventing effect. This genotype-drug interaction is mechanistically important; see Contradictions. (sources/channelopathies-jaha-2025)
- Isoproterenol for electrical storm: Class IIb (ESC 2022). (sources/VA-SCD-ESC-2022)
- Pharmacological data are limited and primarily focused on SQTS1; genotype-targeted drug research for SQT2–8 is an unmet need. (sources/channelopathies-jaha-2025)
Contradictions / Open Questions
- Amiodarone/sotalol paradox in SQTS1: Despite both being IKr blockers, amiodarone and sotalol are clinically ineffective in SQTS1 — whose primary pathogenesis is KCNH2 gain-of-function. The gain-of-function mutation alters drug-channel binding kinetics so that standard IKr-blocking drugs cannot exert their expected effect. This mechanistic exception undermines the assumption that channel-blocking drugs reliably reverse channel gain-of-function, a lesson relevant across channelopathies. (sources/channelopathies-jaha-2025)
- SupRep for SQTS1 — silencing without replacement: Gene therapy for SQTS1 requires only shRNA silencing of the gain-of-function KCNH2 allele, with no replacement cDNA needed — the opposite of the SupRep approach for LQT2 (where silencing is followed by replacement). Over-silencing KCNH2 in a SQTS1 patient risks inducing iatrogenic LQT2. The therapeutic window for silencing-only has not been established in humans. (sources/gene-therapy-arrhythmia-2025)
- ESC 2022 diagnostic threshold expansion: ESC 2022 expanded SQTS diagnosis to QTc ≤360 ms with additional criteria (vs. the prior QTc <340 ms threshold). This broader definition captures more patients but may reduce specificity — a healthy individual with borderline short QTc can now qualify with a single additional feature such as a family history of unexplained sudden death, which itself may be undiagnosed SQTS. The net sensitivity/specificity of the revised criteria has not been prospectively validated. (sources/VA-SCD-ESC-2022, sources/channelopathies-jaha-2025)
- PRS entirely unstudied in SQTS: Common variant genetic modifiers of SQTS susceptibility or severity have not been investigated. By analogy with LQTS, QTc-shortening common variants may modulate SQTS penetrance and severity — but this awaits dedicated investigation. (sources/repolarisation-jaccep-2023)
Connections
- Related to concepts/Cardiac-Action-Potential
- Related to concepts/Schwartz-Score
- Related to concepts/Ion-Channel-Mutations
- Related to concepts/Sudden-Cardiac-Death
- Related to entities/Early-Repolarization-Syndrome
- Related to entities/KCNQ1
- Related to entities/KCNH2
- Related to entities/KCNJ2
- Related to concepts/Electrical-Storm
- Related to concepts/SupRep-Therapy
- Related to concepts/Cardiogenetic-Centers
- Related to concepts/Cardiac-Repolarization
- Related to concepts/Polygenic-Risk-Score
- Related to sources/channelopathies-jaha-2025
- Related to sources/arrhythmia-genetics-mgenetik-2025
- Related to sources/repolarisation-jaccep-2023
- Related to sources/VA-SCD-ESC-2022
- Related to sources/gene-therapy-arrhythmia-2025